CEO Dai Takehara will participate in the “103rd IR Seminar for Individual Investors” hosted by Logmi Finance on Saturday, May 17, 2025. As a company committed to sustainable growth and corporate value enhancement, we actively promote dialogue with shareholders and investors through our proactive IR activities. We will continue our efforts to communicate information and...

Nikkei Biotech has published an interview with our CEO Dai Takehara, and our Director/Head of R&D Dr. Park. Special Feature: Peptide Drug Discovery Finally Taking Off “The Future of PPI Drug Discovery: A Conversation with PRISM BioLab CEO Dai Takehara” https://bio.nikkeibp.co.jp/atcl/news/p1/25/04/15/13203/

PRISM BioLab has been featured in The Nikkei (Nihon Keizai Shimbun). “PRISM BioLab and AI Drug Discovery Startup Partner for Efficient Drug Development” https://www.nikkei.com/article/DGXZQOUC1173U0R10C25A4000000/

TOKYO, Japan, 14 April 2025 — PRISM BioLab, Co. Ltd., a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery collaboration with Elix, Inc., effective April 1, 2025. This partnership will accelerate research on these challenging molecular targets by...

Our CEO, Takehara, recently appeared on Radio NIKKEI 1’s The Money – Thursday, Hideaki Sakurai’s Kabutetsu. Broadcast Date & Time: Thursday, March 13, 2025, 14:30–16:00 (JST) The recorded broadcast is available for a limited time. You can check out the March 13 episode via Radiko or Podcast here: http://www.radionikkei.jp/themoney/20250313.html

We are pleased to announce that our CEO, Takehara, will be speaking at Miyaman’s Venture Talk vol.12, hosted by the Life Science Innovation Network Japan (LINK-J). In this event, he will join Mr. Miyata to discuss the latest advancements in the development of protein-protein interaction inhibitors. Event Details: Date & Time: Friday, March 7, 2025,...

We are pleased to announce that at our Ordinary General Meeting of Shareholders held on December 26, 2024, the following director was appointed and assumed office as of the same date: Director : Shinji Takeuchi (General Manager, Administration Department) Additionally, Director Tomohiro Maeda resigned from his position effective December 26, 2024.

Our CEO, Takahara, recently appeared on IRTV, a video platform connecting investors and companies. YouTube: IRTV – “July 2, 2024 IPO! Discover the Secrets of PepMetics® Technology: A New Era in Drug Discovery” https://youtu.be/7_xlnd5ECQ4

On Wednesday, November 13, 2024, our CTO, Toma, delivered a presentation at the symposium titled “Chemistry in Next-Generation Drug Discovery: Fusion of AI, Automation, and Molecular Conversion.” The event was co-hosted by LINK-J and Merck Ltd. Japan, and took place both at the Nihonbashi Life Science Hub and online. Read the full event report here:...